Format

Send to

Choose Destination
J Int AIDS Soc. 2014 Sep 8;17(3 Suppl 2):19154. doi: 10.7448/IAS.17.3.19154. eCollection 2014.

ARV-based HIV prevention for women - where we are in 2014.

Author information

1
FHI 360, Durham, North Carolina, USA; tmastro@fhi360.org.
2
FHI 360, Durham, North Carolina, USA.
3
CAPRISA, Durban, South Africa.

Abstract

Women continue to be at special risk for HIV acquisition due to a complex mix of biological, behavioural, structural, cultural and social factors, with unacceptable rates of new infection. Scientific advances over the past decade have highlighted the use of antiretroviral (ARV) drugs as pre-exposure prophylaxis (PrEP) to prevent HIV acquisition (sexually, parenterally and vertically) and ARV treatment (ART) for HIV-positive patients to prevent onward transmission (treatment as prevention - TasP). This paper reviews the evidence base for PrEP and TasP, describes new products in development and the need to translate research findings into programmes with impact at the population level.

KEYWORDS:

AIDS; HIV; HIV prevention; HIV treatment; PrEP; antiretroviral agents; women

PMID:
25224614
PMCID:
PMC4164013
DOI:
10.7448/IAS.17.3.19154
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center